Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jpc.15977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone.
Children (Basel)
January 2025
Pediatric Research Center, New Children's Hospital, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland.
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to antibody formation. In 2021, localized lipoatrophy was observed in 14.
View Article and Find Full Text PDFPrognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis.
Biomedicines
December 2024
Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey.
The course of relapsing-remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND).
View Article and Find Full Text PDFKinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome.
Front Pharmacol
January 2025
Department of Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Purpose: Rituximab has proven efficacy in children with idiopathic nephrotic syndrome (INS). However, vast majority of children inevitably experience relapse with B-cell repletion, necessitating repeat course of rituximab, which may increase the risk of adverse effects. The timing of additional dosing and optional dosing regimen of rituximab in pediatric patients with INS have yet to be determined.
View Article and Find Full Text PDFInterobserver reliability of Pirani scoring for idiopathic clubfoot in walking-age children.
J Pediatr Orthop B
January 2025
Department of Paediatric Orthopaedics, Chacha Nehru Bal Chikitsalaya, Delhi, India.
Pirani scoring system is one of the most commonly used tools to assess the initial deformity, monitor the treatment progression, and identify relapse in clubfoot. The method has been demonstrated to correlate well with the sequential correction of deformity for children under age 1 year. We conducted a study to examine the interobserver reliability of Pirani scores in children of walking-age.
View Article and Find Full Text PDFPrevalence and Risk Factors for Leg Length Discrepancy in Children With Idiopathic Clubfoot Treated With Ponseti Method.
J Pediatr Orthop
January 2025
Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO.
Introduction: Clubfoot is at times associated with other lower extremity abnormalities, such as leg length discrepancy (LLD). Initial studies in patients treated with extensive soft tissue release (STR) have estimated that LLD is prevalent in 9% to 11% of children with idiopathic clubfoot. However, Ponseti-style serial casting has since replaced STR as the preferred clubfoot treatment method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!